First Double-Blind Trial of Alzheimer’s Treatment with Positive Outcomes for Memory, Behavior, and Daily Functioning

OPEN MINDS On-Line News Galantamine hydrobromide, an investigational treatment for Alzheimer's disease, may not only improve patients' memory, but also may delay loss of functioning and the emergence of behavioral symptoms, according to a study published in the June 27 issue of Neurology, a journal of the American Academy of Neurology. This is the first double-blind study to show positive results for an Alzheimer's treatment in all three types of disability commonly associated with the disorder. In the multi-center, double-blind, placebo-controlled study, 978 patients with mild to moderate Alzheimer's disease were randomized . . .